CareDx, Inc. stands out in the transplant diagnostics landscape with a focused portfolio of non-invasive molecular tests complemented by digital health and patient support solutions. Its integrated approach drove a 15% revenue growth in 2025, fueled by expanding test volumes and digital offerings, yet the company reported operating losses reflecting high R&D and competitive pressures. Aggressive share repurchases characterize capital allocation over dividends, while ongoing regulatory investigations and pricing dynamics underscore risk factors. Watch for clinical trial readouts and reimbursement developments as key drivers influencing CareDx’s path toward sustained profitability.